BioWorld Today, one of the leading news sites for the biotech industry from Thomson Reuters, has labelled Antimicrobial peptides (AMPs), such as SAAP-148 that is developed by Madam Therapeutics, as one of the exiting developments in the anti-microbial development space.
“Antimicrobial resistance (AMR) is a topic that just won’t go away, and for good reason”, according to BioWorld. “Despite the plethora of threats facing humankind, including thousands of diseases in need of therapies or cures, many scientists worry that the biggest risk of extinction comes from the deadly pathogens that exist in uneasy cohabitation on planet Earth”.
Tensions mounted in 2015 after the mcr-1 gene was detected on plasmids in China and Europe and were heightened last year with the first U.S. case of a patient with an infection resistant to a last-resort antibiotic. But academics remain hard at work, and more small companies are moving into the space. Antimicrobial peptides (AMPs) – like SAAP-148- in particular – are among the newest kids on the block.
BioWorld Today highlights that AMPs have shown the ability to kill a broad spectrum of gram-negative and gram-positive bacteria, enveloped viruses, fungi and even cancerous cells. AMPs also may offer the prospect of enhancing immunity by functioning as immunomodulators.